Agenus Inc.
AGEN- 1M
- -26.4%
Agenus Inc. in brief
Agenus Inc. is a listed company in the Biotechnology industry, based in Lexington, Massachusetts, USA. It was founded in 1994. Its market value was $290 M on 22 October 2026, which makes it the 14,929th largest listed company in the world and the 2,909th largest in the USA on this site. In the year to December 2025 it had sales of $114 M and a net loss of $3 M. It employs about 441 people and Garo H. Armen is its chief executive. Its largest product and service lines by sales in 2025 were Pre-Commercial Product Revenue (4%), Service Revenue (under 1%) and Research and Development (under 1%). By market, the largest shares of its 2025 sales came from USA (99%). Its shares trade under the symbol AGEN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Agenus Inc.
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Agenus Inc. timeline
- 1994
- 🏁
- 1999
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2000
- 🔔· approximateInitial public offering on Nasdaq as AGEN
- 2011
- ✎Renamed Agenus IncFormerly Antigenics Inc /De/.
- 2018
- •Legal Entity Identifier issuedLEI 529900NDQQGU5H4UJK81 registered.
- 2023
- 💰Record revenue of $156 millionFY2023, the highest of the 7 years on record.
Events of Agenus Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,422 (Jan 2020) · #2,601 (Jan 2021) · #2,797 (Jan 2022) · #2,260 (Dec 2022) · #2,630 (Jul 2023) · #2,940 (Jan 2024) · #1,938 (Mar 2026) · #2,798 (Aug 2026) · #2,672 (Sep 2026) · #2,913 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- 9.4×
- Price / sales (TTM)
- 2.2×
- Price / book
- —
- Free cash flow yield
- -26.7%
- Net margin (TTM)
- 23.0%
- Operating margin
- -17.7%
- Return on equity
- —
- Liabilities / assets
- 222.5%
- Net debt
- $42M
- Revenue growth
- +10.4%
- R&D / revenue
- 69.5%
- Revenue per employee
- $259 K
- Profit per employee
- $-7 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $114M | +10.4% | $-20M | $-3M | -2.7% |
| Dec 2024 | $103M | -33.8% | $-120M | $-232M | -224.5% |
| Dec 2023 | $156M | +59.5% | $-160M | $-257M | -164.7% |
| Dec 2022 | $98M | — | $-179M | $-231M | -235.3% |
| Dec 2021 | — | — | $26M | $-29M | — |
| Dec 2020 | $88M | -41.2% | $-117M | $-183M | -207.4% |
| Dec 2019 | $150M | +308.0% | $-70M | $-112M | -74.3% |
| Dec 2018 | $37M | — | $-124M | $-162M | -440.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-77M | $0M | $-77M | $0.00 | — |
| Dec 2024 | $-158M | $1M | $-159M | $-10.59 | — |
| Dec 2023 | $-224M | $10M | $-234M | $-13.75 | — |
| Dec 2022 | $-175M | $53M | $-228M | $-15.64 | — |
| Dec 2021 | $10M | $34M | $-24M | $-0.11 | — |
| Dec 2020 | $-139M | $3M | $-143M | $-1.05 | — |
| Dec 2019 | $-19M | $5M | $-23M | $-0.80 | — |
| Dec 2018 | $-131M | $4M | $-135M | $-1.44 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $31M (+4.1% on a year earlier), net income $3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportResults of operations
- Aug 18, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
- Aug 13, 20268-KCurrent reportDirectors or officers changed
- Aug 11, 20268-KCurrent reportDirectors or officers changed
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jul 13, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure · Other events
- Jul 6, 20268-KCurrent reportMaterial agreement
- Jun 23, 20268-KCurrent reportShareholder vote
- May 15, 20268-KCurrent reportDirectors or officers changed
- May 11, 202610-QQuarterly report · period to Mar 2026
Official filings of Agenus Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $114 M
- Operating income
- $-20 M
- Net income
- $-3 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $227 M
- Total liabilities
- $505 M
- Total equity
- $-271 M
As of December-2025
Top 100 institutional investors in Agenus Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Ra Capital Management, L.P. | 4,122,000 | New | 9.11% | $41 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 2,937,807 | +372,923 (+14.54%) | 6.49% | $29 M | Nov 13, 2026 |
| 3 | Eventide Asset Management, LLC | 2,446,789 | New | 5.41% | $24 M | Nov 13, 2026 |
| 4 | Siren, L.L.C. | 2,419,263 | +1,355,013 (+127.32%) | 5.35% | $24 M | Nov 12, 2026 |
| 5 | Commodore Capital LP | 1,985,387 | New | 4.39% | $20 M | Nov 16, 2026 |
| 6 | Vanguard Capital Management LLC | 1,687,245 | +11,149 (+0.67%) | 3.73% | $17 M | Nov 13, 2026 |
| 7 | Vanguard Portfolio Management LLC | 1,367,782 | -59,805 (-4.19%) | 3.02% | $14 M | Nov 13, 2026 |
| 8 | Geode Capital Management, LLC | 1,011,641 | -23,399 (-2.26%) | 2.24% | $10 M | Nov 6, 2026 |
| 9 | Goldman Sachs Group Inc | 825,001 | +376,618 (+83.99%) | 1.82% | $8 M | Nov 16, 2026 |
| 10 | Marshall Wace, LLP | 786,350 | +346,729 (+78.87%) | 1.74% | $8 M | Nov 13, 2026 |
| 11 | State Street Corp | 756,378 | +343,995 (+83.42%) | 1.67% | $8 M | Nov 12, 2026 |
| 12 | TCG Crossover Management, LLC | 603,892 | New | 1.33% | $6 M | Nov 16, 2026 |
| 13 | Globeflex Capital L P | 418,581 | 0 (0.00%) | 0.93% | $4 M | Nov 16, 2026 |
| 14 | Morgan Stanley | 381,104 | +119,036 (+45.42%) | 0.84% | $4 M | Nov 13, 2026 |
| 15 | Northern Trust Corp | 297,170 | -16,882 (-5.38%) | 0.66% | $3 M | Nov 16, 2026 |
| 16 | Renaissance Technologies LLC | 281,326 | +52,980 (+23.20%) | 0.62% | $3 M | Nov 12, 2026 |
| 17 | Vanguard Fiduciary Trust Co | 242,638 | -28,976 (-10.67%) | 0.54% | $2 M | Nov 13, 2026 |
| 18 | D. E. Shaw & Co., Inc. | 239,718 | New | 0.53% | $2 M | Nov 16, 2026 |
| 19 | Susquehanna International Group, LLP | 235,190 | +193,174 (+459.76%) | 0.52% | $2 M | Nov 16, 2026 |
| 20 | UBS Group AG | 207,677 | +188,401 (+977.39%) | 0.46% | $2 M | Nov 10, 2026 |
| 21 | XTX Topco Ltd | 179,011 | +147,361 (+465.60%) | 0.40% | $2 M | Nov 16, 2026 |
| 22 | Connor, Clark & Lunn Investment Management Ltd. | 158,447 | -151,588 (-48.89%) | 0.35% | $2 M | Nov 10, 2026 |
| 23 | Two Sigma Investments, LP | 157,185 | +58,500 (+59.28%) | 0.35% | $2 M | Nov 16, 2026 |
| 24 | First Trust Advisors LP | 152,562 | New | 0.34% | $2 M | Nov 12, 2026 |
| 25 | AQR Capital Management LLC | 151,615 | New | 0.34% | $2 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Point72 Asset Management, L.P. | 150,831 | New | 0.33% | $1 M | Nov 16, 2026 |
| 27 | Wellington Management Group LLP | 143,777 | New | 0.32% | $1 M | Nov 16, 2026 |
| 28 | Susquehanna Portfolio Strategies, LLC | 143,408 | -15,329 (-9.66%) | 0.32% | $1 M | Nov 16, 2026 |
| 29 | Prudential Financial Inc | 128,052 | +108,642 (+559.72%) | 0.28% | $1 M | Nov 16, 2026 |
| 30 | Bank of New York Mellon Corp | 124,155 | +22,382 (+21.99%) | 0.27% | $1 M | Nov 5, 2026 |
| 31 | Citadel Advisors LLC | 124,141 | New | 0.27% | $1 M | Nov 16, 2026 |
| 32 | Charles Schwab Investment Management Inc | 111,339 | +11,947 (+12.02%) | 0.25% | $1 M | Nov 16, 2026 |
| 33 | Panagora Asset Management Inc | 99,246 | -80,343 (-44.74%) | 0.22% | $1 M | Nov 12, 2026 |
| 34 | Nuveen, LLC | 79,850 | New | 0.18% | $1 M | Nov 10, 2026 |
| 35 | Jane Street Group, LLC | 64,387 | New | 0.14% | $1 M | Nov 12, 2026 |
| 36 | Man Group plc | 63,254 | -277,171 (-81.42%) | 0.14% | $1 M | Nov 16, 2026 |
| 37 | HighTower Advisors, LLC | 57,791 | New | 0.13% | $1 M | Nov 10, 2026 |
| 38 | Price T Rowe Associates Inc /MD/ | 57,656 | 0 (0.00%) | 0.13% | $1 M | Nov 16, 2026 |
| 39 | Rhumbline Advisers | 50,631 | +21,143 (+71.70%) | 0.11% | $1 M | Nov 10, 2026 |
| 40 | Strs Ohio | 46,500 | -30,400 (-39.53%) | 0.10% | $0 M | Oct 30, 2026 |
| 41 | Jpmorgan Chase & Co | 45,411 | +28,294 (+165.30%) | 0.10% | $0 M | Nov 12, 2026 |
| 42 | Captrust Financial Advisors | 38,870 | +9,898 (+34.16%) | 0.09% | $0 M | Nov 12, 2026 |
| 43 | Bank Of America Corp /de/ | 35,597 | -16,415 (-31.56%) | 0.08% | $0 M | Nov 16, 2026 |
| 44 | Invesco Ltd. | 35,558 | -15,380 (-30.19%) | 0.08% | $0 M | Nov 12, 2026 |
| 45 | Creative Planning | 34,652 | New | 0.08% | $0 M | Nov 2, 2026 |
| 46 | Deutsche Bank AG\ | 33,816 | -5,088 (-13.08%) | 0.07% | $0 M | Nov 6, 2026 |
| 47 | Vanguard Global Advisers, LLC | 33,746 | +17,840 (+112.16%) | 0.07% | $0 M | Nov 13, 2026 |
| 48 | Vanguard Personalized Indexing Management, LLC | 29,618 | +10,419 (+54.27%) | 0.07% | $0 M | Nov 16, 2026 |
| 49 | Claro Advisors Inc. | 26,196 | -7,154 (-21.45%) | 0.06% | $0 M | Nov 2, 2026 |
| 50 | LPL Financial LLC | 24,177 | +11 (+0.05%) | 0.05% | $0 M | Nov 6, 2026 |
| 51 | Osaic Holdings, Inc. | 23,450 | -10 (-0.04%) | 0.05% | $0 M | Nov 12, 2026 |
| 52 | State of Wyoming | 22,701 | New | 0.05% | $0 M | Oct 28, 2026 |
| 53 | Squarepoint Ops LLC | 22,425 | New | 0.05% | $0 M | Nov 9, 2026 |
| 54 | MetLife Investment Management, LLC | 22,271 | New | 0.05% | $0 M | Nov 16, 2026 |
| 55 | Group One Trading LLC | 20,456 | +19,895 (+3546.35%) | 0.05% | $0 M | Nov 10, 2026 |
| 56 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 18,304 | -43 (-0.23%) | 0.04% | $0 M | Nov 16, 2026 |
| 57 | Wells Fargo & Company/mn | 18,243 | -24,974 (-57.79%) | 0.04% | $0 M | Nov 16, 2026 |
| 58 | Blueshift Asset Management, LLC | 17,791 | New | 0.04% | $0 M | Nov 13, 2026 |
| 59 | FMR LLC | 16,438 | +3,156 (+23.76%) | 0.04% | $0 M | Nov 10, 2026 |
| 60 | Millennium Management LLC | 16,351 | New | 0.04% | $0 M | Nov 16, 2026 |
| 61 | Key Client Fiduciary Advisors, LLC | 15,536 | -8,589 (-35.60%) | 0.03% | $0 M | Oct 19, 2026 |
| 62 | Bank Of Montreal /can/ | 15,515 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 63 | Barclays PLC | 14,832 | +5,635 (+61.27%) | 0.03% | $0 M | Nov 6, 2026 |
| 64 | Brown Advisory Inc | 14,000 | New | 0.03% | $0 M | Nov 16, 2026 |
| 65 | HSBC Holdings PLC | 13,525 | +2,349 (+21.02%) | 0.03% | $0 M | Nov 16, 2026 |
| 66 | Lazard Asset Management LLC | 12,801 | New | 0.03% | $0 M | Nov 16, 2026 |
| 67 | Post Resch Tallon Group Inc. | 12,750 | 0 (0.00%) | 0.03% | $0 M | Oct 9, 2026 |
| 68 | Alliancebernstein L.P. | 12,380 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 69 | Greenwich Wealth Management LLC | 12,000 | New | 0.03% | $0 M | Nov 16, 2026 |
| 70 | Abel Hall, LLC | 11,987 | +227 (+1.93%) | 0.03% | $0 M | Oct 19, 2026 |
| 71 | Values First Advisors, Inc. | 10,793 | -191 (-1.74%) | 0.02% | $0 M | Oct 23, 2026 |
| 72 | Baird Financial Group, Inc. | 10,620 | New | 0.02% | $0 M | Nov 13, 2026 |
| 73 | Manufacturers Life Insurance Company, The | 10,297 | New | 0.02% | $0 M | Nov 13, 2026 |
| 74 | Everhart Financial Group, Inc. | 10,100 | New | 0.02% | $0 M | Oct 8, 2026 |
| 75 | Police & Firemen's Retirement System of New Jersey | 10,042 | -5,300 (-34.55%) | 0.02% | $0 M | Nov 9, 2026 |
| 76 | BNP Paribas Financial Markets | 8,282 | -13,614 (-62.18%) | 0.02% | $0 M | Nov 12, 2026 |
| 77 | Russell Investments Group, Ltd. | 5,732 | +2,118 (+58.61%) | 0.01% | $0 M | Nov 6, 2026 |
| 78 | Legal & General Group Plc | 3,864 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 79 | Ameritas Investment Partners, Inc. | 3,616 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 80 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3,396 | +3,111 (+1091.58%) | 0.01% | $0 M | Nov 16, 2026 |
| 81 | Pinnacle Wealth Planning Services, Inc. | 3,373 | 0 (0.00%) | 0.01% | $0 M | Oct 27, 2026 |
| 82 | Federated Hermes, Inc. | 2,887 | -493 (-14.59%) | 0.01% | $0 M | Nov 12, 2026 |
| 83 | Caitong International Asset Management Co., Ltd | 2,215 | +582 (+35.64%) | 0.00% | $0 M | Oct 29, 2026 |
| 84 | New York State Common Retirement Fund | 2,100 | -16,800 (-88.89%) | 0.00% | $0 M | Nov 17, 2026 |
| 85 | Arax Advisory Partners | 2,086 | +2,081 (+41620.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 86 | Royal Bank Of Canada | 2,075 | +163 (+8.53%) | 0.00% | $0 M | Nov 16, 2026 |
| 87 | Citigroup Inc | 1,882 | -25,820 (-93.21%) | 0.00% | $0 M | Nov 4, 2026 |
| 88 | Atlantic Union Bankshares Corp | 1,750 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 89 | Tower Research Capital LLC (TRC) | 1,378 | -933 (-40.37%) | 0.00% | $0 M | Nov 16, 2026 |
| 90 | Chilton Capital Management LLC | 1,058 | 0 (0.00%) | 0.00% | $0 M | Oct 28, 2026 |
| 91 | Optiver Holding B.V. | 1,014 | +440 (+76.66%) | 0.00% | $0 M | Nov 16, 2026 |
| 92 | Covestor Ltd | 915 | 0 (0.00%) | 0.00% | $0 M | Oct 30, 2026 |
| 93 | Nisa Investment Advisors, LLC | 847 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 94 | Sterling Capital Management LLC | 830 | +125 (+17.73%) | 0.00% | $0 M | Oct 22, 2026 |
| 95 | GAMMA Investing LLC | 787 | New | 0.00% | $0 M | Oct 8, 2026 |
| 96 | SBI Securities Co., Ltd. | 695 | +683 (+5691.67%) | 0.00% | $0 M | Oct 22, 2026 |
| 97 | Physician Wealth Advisors, Inc. | 682 | +61 (+9.82%) | 0.00% | $0 M | Oct 20, 2026 |
| 98 | Huntington National Bank | 664 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 99 | Northwestern Mutual Wealth Management Co | 633 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 100 | Game Plan Financial Advisors, LLC | 585 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Agenus Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.16 M | $4 M | 2.6% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 435,952 | $3 M | 0.96% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 903,711 | $3 M | 2.0% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 290,646 | $2 M | 0.64% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Strategic Equity FundThe Vanguard Group, Inc. | 511,809 | $2 M | 1.1% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 485,158 | $1 M | 1.1% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 258,455 | $1 M | 0.57% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 256,842 | $1 M | 0.57% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 96,310 | $1 M | 0.21% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 205,345 | $1 M | 0.45% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 163,921 | $1 M | 0.36% | <0.01% | +25% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 133,984 | $0 M | 0.30% | 0.03% | +65% | Jun 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 114,747 | $0 M | 0.25% | 0.02% | −25% | Jun 30, 2026 |
| 🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION | 84,700 | $0 M | 0.19% | 0.12% | new | May 31, 2026 |
| 🇺🇸 PGIM Quant Solutions Small-Cap Value FundPGIM INVESTMENTS LLC | 39,500 | $0 M | 0.09% | 0.07% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 74,480 | $0 M | 0.16% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 60,552 | $0 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 50,643 | $0 M | 0.11% | <0.01% | +6.1% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 23,081 | $0 M | 0.05% | <0.01% | +33% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 47,606 | $0 M | 0.11% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 19,052 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC | 45,503 | $0 M | 0.10% | 0.12% | — | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 40,407 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 39,218 | $0 M | 0.09% | <0.01% | +94% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 15,259 | $0 M | 0.03% | <0.01% | +29% | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 15,000 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc. | 33,574 | $0 M | 0.07% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 31,100 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 22,604 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 24,500 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 21,138 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 20,381 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 6,714 | $0 M | 0.01% | 0.01% | +28% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 4,666 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 11,017 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 10,885 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 4,329 | $0 M | <0.01% | <0.01% | +25% | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 9,037 | $0 M | 0.02% | 0.01% | +56% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 8,388 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,415 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 8,258 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 2,763 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 6,177 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 6,190 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 6,190 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 6,078 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 5,605 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 5,194 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 4,868 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 3,616 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,181 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 2,466 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 2,091 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,778 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 1,209 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 451 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,006 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 834 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 710 | $0 M | <0.01% | <0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 551 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 500 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 204 | $0 M | <0.01% | <0.01% | +13% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 62 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Agenus Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Thomas L. HarrisonDirector | Grant or award | +4,443 | $6.893 | $31 K | 51,988 | Form 4 |
| filed | Garo H. ArmenSee Remarks, Director | Grant or award | +4,852 | $3.350 | $16 K | 371,108 | Form 4 |
| filed | Thomas L. HarrisonDirector | Grant or award | +8,547 | $3.580 | $31 K | 47,545 | Form 4 |
| filed | Garo H. ArmenSee Remarks, Director | Grant or award | +5,364 | $3.030 | $16 K | 366,256 | Form 4 |
| filed | Garo H. ArmenSee Remarks, Director | Grant or award | +4,925 | $3.300 | $16 K | 360,892 | Form 4 |
| filed | Garo H. ArmenSee Remarks, Director | Grant or award | +4,644 | $3.500 | $16 K | 355,967 | Form 4 |
| filed | Garo H. ArmenSee Remarks, Director | Grant or award | +4,540 | $3.580 | $16 K | 351,323 | Form 4 |
| filed | Garo H. ArmenSee Remarks, Director | Grant or award | +4,233 | $3.840 | $16 K | 346,783 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Agenus Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2010 | Q4 2011 | $0M |
| Q3 2010 | Q3 2011 | $0M |
Trading halts
- 2025-12-19 15:43 UTC, code LUDP, resumed 15:48 UTC
- 2025-12-19 15:33 UTC, code LUDP, resumed 15:43 UTC
- 2025-06-03 10:55 UTC, code T3, resumed 11:30 UTC
Fails to deliver
- : 995 shares at $6.40
- : 23 shares at $8.70
- : 108 shares at $8.33
- : 69 shares at $7.85
- : 22 shares at $7.22
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Agenus Inc. scorecard#
Passes 8 of the 18 checks that could be worked out: strongest in valuation (3 of 5), weakest in financial health (0 of 3). Fiscal year 2025; market cap of Oct 22, 2026.
Valuation3 of 5
- ✓P/E below its peers' median9.4×P/E 9.4× against Biotechnology's median of 17.5×.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median2.2×Price to sales 2.2× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-26.7%Free cash flow is -26.7% of the market value.
- ✓Earnings yield above the 10-year Treasury yield10.6%Earnings yield 10.6% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 5
- ✓Revenue grew in the newest year10.4%Revenue up 10.4% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years5.2%5.2% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median5.2%5.2% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year0.00 vs -10.59Diluted EPS 0.00 in fiscal 2025 against -10.59 the year before (report's currency).
- ✓Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$183 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability2 of 4
- ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-17.7%-17.7% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-17.7%-17.7% in fiscal 2025 against -183.1% in 2022.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.41 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-13.93Z-score -13.93 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year38.5%Diluted shares up 38.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Agenus Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -17.7% | -60.5% | |
| Net margin | -2.7% | -68.9% | |
| Revenue growth, 3 years a year | 5.2% | 12.9% | |
| Revenue growth | 10.4% | 15.8% | |
| Free cash flow margin | -67.6% | -61.5% |
4of 9on the Piotroski tests of financial strength
- Net loss of $3 million, the 17th loss-making year in a row.
- Free cash flow was negative: -$77 million.
- The share count rose 38.5% in the year.
- Shareholders' equity is negative: -$271 million.
Agenus Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 114+10.4%100% | 103−33.8%100% | 156+59.5%100% | 98−66.8%100% | 296+235%100% | 88−41.2%100% | 150+308%100% | 37r37−14.2%100% | 43+89.9%100% | 23—100% | |
| Cost of revenue | 1.0+110%0.9% | 0.5−84.4%0.5% | 3.1−70.6%2.0% | 11+205%10.8% | 3.5+47.7%1.2% | 2.3—2.7% | — | — | — | — | |
| Research and development | 79−49.0%69.5% | 156−33.7%150% | 235+25.6%150% | 187+4.5%190% | 179+25.2%60.4% | 143−15.3%162% | 168+35.1%112% | 125r125+7.3%339% | 116r116+22.3%271% | 95—421% | |
| General and administrative | 54−24.3%47.6% | 72−8.7%69.5% | 79−2.8%50.4% | 81+6.1%82.6% | 76+28.9%25.8% | 59+28.6%67.2% | 46+23.3%30.7% | 37r37+10.7%102% | 34r34+1.9%78.7% | 33—147% | |
| Operating income | −20—−17.7% | −120—−116% | −160—−102% | −179−797%−183% | 26—8.7% | −117—−133% | −70—−46.7% | −124r−124—−337% | −104r−104—−242% | −107—−476% | |
| Interest and finance income | 0.3−87.7%0.3% | 2.8−52.9%2.7% | 5.9+163%3.8% | 2.3—2.3% | — | — | — | — | — | — | |
| Interest expense and finance costs | 56−53.8%48.7% | 120+15.9%116% | 104+62.0%66.4% | 64—65.4% | — | — | — | — | 31+61.3%73.1% | 19—86.0% | |
| Provision for credit losses | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | — | — | — | — | |
| Share of profit of associates | −26—−23.1% | 0—0.0% | 0—0.0% | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | −2.2−138%−1.9% | 5.8+15657%5.6% | 0.0−99.7%0.0% | 13+149%12.8% | 5.1—1.7% | −1.9−6736%−2.1% | 0.0—0.0% | −2.2r−2.2−210%−5.9% | 2.0r2.0—4.6% | −2.2—−9.8% | |
| Income before tax | −3.1—−2.7% | −232—−224% | −257—−165% | — | — | — | — | — | −121—−281% | −127—−563% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income including minority interests | −3.1—−2.7% | −232—−224% | −257r−257—−165% | −231r−231—−235% | −29r−29—−9.7% | −183r−183—−207% | −112—−74.3% | −162r−162—−441% | −121r−121—−281% | −127—−563% | |
| Minority interests' share of net income | −3.2—−2.8% | −5.1—−4.9% | −12—−7.5% | −11—−10.8% | −4.8—−1.6% | −2.0—−2.2% | −3.9—−2.6% | −2.4r−2.4—−6.4% | — | — | |
| Net income attributable to shareholders | — | — | — | — | — | — | — | — | −121—−281% | −127—−563% | |
| Earnings per share, basic | 0.00—— | -10.59—— | -13.75r-0.69—— | -15.64r-0.78—— | -0.11—— | -1.05—— | -0.80—— | -1.44—— | -1.23—— | -1.46—— | |
| Earnings per share, diluted | 0.00—— | -10.59—— | -13.75r-0.69—— | -15.64r-0.78—— | -0.11—— | -1.05—— | -0.80—— | -1.44—— | -1.23—— | -1.46—— | |
| Shares, weighted average (basic) | 30+38.5%— | 21+20.0%— | 18r0.4+27.0%— | 14r0.3+6054%— | 0.2+32.7%— | 0.2—— | — | — | — | — | |
| Shares, weighted average (diluted) | 30+38.5%— | 21+20.0%— | 18r0.4+27.0%— | 14r0.3+6054%— | 0.2+32.7%— | 0.2+27.8%— | 0.1+21.9%— | 0.1r111+12.6%— | 0.1r98−99.9%— | 87—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 3.0−92.6%1.3% | 40−46.9%17.9% | 76−57.4%24.2% | 179−38.8%43.2% | 292+192%62.7% | 100+61.6%46.6% | 62+16.5%39.8% | 53r53−11.9%38.9% | 60−15.8%43.5% | 71—45.5% | |
| Short-term investments | 0—0.0% | — | — | 15−2.1%3.6% | 15—3.2% | — | — | — | — | 5.0—3.2% | |
| Receivables | 1.8+350%0.8% | 0.4−98.4%0.2% | 26+843%8.2% | 2.7+80.6%0.7% | 1.5+31.2%0.3% | 1.2−92.9%0.5% | 16+1637%10.5% | 0.9r0.9−17.3%0.7% | 1.1−90.0%0.8% | 11—7.2% | |
| Inventory | — | — | — | — | — | — | 0−100%0.0% | 0.1r0.1−30.8%0.0% | 0.1−9.9%0.1% | 0.1—0.1% | |
| Other current assets | 1.1−54.9%0.5% | 2.4+1.8%1.1% | 2.4−25.7%0.8% | 3.2+0.7%0.8% | 3.2+57.8%0.7% | 2.0+97.9%0.9% | 1.0−32.2%0.7% | 1.5r1.5+38.3%1.1% | 1.1+29.0%0.8% | 0.8—0.5% | |
| Current assets | 133+193%58.8% | 46−59.5%20.1% | 112−47.3%35.8% | 213−35.8%51.5% | 332+192%71.2% | 114+31.5%53.0% | 87+15.7%55.7% | 75r75+1.7%54.8% | 74−19.4%53.1% | 91—58.2% | |
| Property, plant and equipment | 15−87.1%6.8% | 120−10.0%53.1% | 133+0.3%42.5% | 133+122%32.2% | 60+124%12.9% | 27+1.8%12.5% | 26+4.8%16.9% | 25r25−4.1%18.4% | 26+2.1%18.9% | 26—16.3% | |
| Right-of-use (leased) assets | 7.7−71.6%3.4% | 27−7.8%12.1% | 30−5.3%9.4% | 31+0.7%7.6% | 31−7.2%6.7% | 33+355%15.6% | 7.4—4.7% | — | — | — | |
| Goodwill | 240.0%10.6% | 24−2.6%10.6% | 25−2.9%7.9% | 25+2.4%6.2% | 25−2.3%5.3% | 25+9.8%11.9% | 23+1.1%14.9% | 23r23−0.5%16.8% | 23+2.9%16.7% | 22—14.3% | |
| Other intangible assets | 3.0−10.0%1.3% | 3.4−23.5%1.5% | 4.4−29.2%1.4% | 6.2−26.6%1.5% | 8.5−22.0%1.8% | 11+3.6%5.1% | 11−14.9%6.8% | 12r12−14.4%9.0% | 14−12.0%10.4% | 16—10.4% | |
| Investments in associates | 24—10.7% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Total assets | 227+0.2%100% | 226−27.9%100% | 314−24.1%100% | 414−11.2%100% | 466+117%100% | 215+38.1%100% | 155+13.9%100% | 136r136−1.4%100% | 138−11.8%100% | 157—100% | |
| Accounts payable | 83+35.0%36.6% | 61+0.0%27.2% | 61+50.1%19.6% | 41+34.3%9.9% | 30+79.2%6.5% | 17+25.4%7.9% | 14−0.4%8.7% | 14r14+68.5%10.0% | 8.1+49.0%5.8% | 5.4—3.5% | |
| Debt due within a year | 45+1555%19.7% | 2.7+1748%1.2% | 0.1−74.6%0.0% | 0.6−21.0%0.1% | 0.7−12.6%0.2% | 0.8+28.9%0.4% | 0.6+342%0.4% | 0.1r0.1−99.3%0.1% | 21+14031%14.9% | 0.1—0.1% | |
| Current liabilities | 323+46.1%143% | 221−13.5%97.8% | 256+35.4%81.5% | 189+20.4%45.7% | 157+20.8%33.7% | 130+6.3%60.5% | 122+79.6%78.7% | 68r68+20.6%49.9% | 56+38.2%40.8% | 41—26.0% | |
| Long-term debt | 0−100%0.0% | 30+139%13.5% | 13+1.5%4.1% | 13−1.9%3.0% | 13−32.1%2.8% | 19+41.1%8.8% | 13+1.3%8.6% | 13r13−90.7%9.7% | 142+9.1%103% | 131—83.2% | |
| Lease liabilities (non-current) | 10−81.5%4.5% | 55−12.7%24.1% | 63−1.3%19.9% | 63+50.4%15.3% | 42+23.6%9.0% | 34+325%15.9% | 8.0—5.2% | — | — | — | |
| Retained earnings | −2,183—−962% | −2,183—−965% | −1,956—−623% | −1,710—−413% | −1,490—−320% | −1,466—−683% | −1,285—−827% | −1,177r−1,177—−863% | −1,026—−742% | −905—−577% | |
| Shareholders' equity | −271—−120% | −326—−144% | −160—−51.1% | −61−278%−14.8% | 34—7.4% | −204—−94.9% | −225—−145% | −172r−172—−126% | −76—−54.8% | −39—−24.9% | |
| Minority interests | −6.8−134%−3.0% | 20+67.0%8.8% | 12+87.4%3.8% | 6.4−52.7%1.5% | 13—2.9% | −7.8—−3.6% | −6.0—−3.9% | −2.1r−2.1—−1.5% | — | — | |
| Total equity | −278—−123% | −306—−135% | −148—−47.3% | −55−215%−13.3% | 48—10.3% | −211—−98.6% | −231—−149% | −175r−175—−128% | −76r−76—−54.8% | −39r−39—−24.9% | |
| Total liabilities and equity | 227+0.2%100% | 226−27.9%100% | 314−24.1%100% | 414−11.2%100% | 466+117%100% | 215+38.1%100% | 155+13.9%100% | 136r136−1.4%100% | 138−11.8%100% | 157—100% | |
| Shares outstanding | 35+49.4%— | 24+19.9%— | 20—— | — | — | — | — | — | — | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 10.0−25.1%8.8% | 13−1.8%12.9% | 14+95.6%8.7% | 6.9+2.3%7.1% | 6.8−5.4%2.3% | 7.2+7.8%8.1% | 6.7+5.9%4.4% | 6.3r6.3+4.7%17.1% | 6.0r6.0+21.4%14.0% | 4.9—21.9% | |
| Share-based compensation | 14−20.8%12.1% | 17−24.0%16.8% | 23+24.7%14.6% | 18−6.3%18.7% | 20+87.9%6.6% | 10+5.3%11.8% | 9.9+29.7%6.6% | 7.6r7.6−38.7%20.7% | 12r12−5.8%29.0% | 13—58.4% | |
| Cash from operating activities | −77—−67.6% | −158—−153% | −224—−143% | −175−1829%−179% | 10—3.4% | −139—−158% | −19—−12.5% | −131r−131—−356% | −94r−94—−220% | −80—−354% | |
| Capital expenditure | −0.0—−0.0% | −0.6—−0.6% | −10.0—−6.4% | −53—−54.1% | −34—−11.4% | −3.5—−3.9% | −4.7—−3.1% | −3.6r−3.6—−9.8% | −3.1r−3.1—−7.3% | −13—−55.5% | |
| Cash from investing activities | 1.2+4322%1.0% | 0.0−99.2%0.0% | 3.4—2.2% | −34—−34.3% | −43—−14.6% | −4.4—−5.0% | −4.7—−3.1% | −3.6r−3.6−274%−9.8% | 2.1r2.1−88.3%4.8% | 18—78.0% | |
| Debt issued | — | — | — | — | — | 6.2—7.0% | — | — | 15—35.0% | — | |
| Debt repaid | −2.5—−2.2% | — | — | — | −0.5—−0.2% | −1.5—−1.7% | — | −162r−162—−440% | — | — | |
| Cash from financing activities | 37−70.2%32.0% | 123+2.5%119% | 120+25.1%76.7% | 96−57.5%97.8% | 225+22.5%76.2% | 184+487%209% | 31−75.6%20.9% | 128r128+59.3%349% | 81r81—188% | −2.5—−10.9% | |
| Change in cash | −39—−34.5% | −36—−34.5% | −102—−65.0% | −113−159%−116% | 192+372%65.0% | 41+365%46.2% | 8.8—5.8% | −7.1r−7.1—−19.4% | −11r−11—−26.3% | −65—−289% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 134+25.4%100% | 31+4.1%100% | 35+34.4%100% | 34+40.2%100% | 34*+27.5%100% | 30+20.4%100% | 26+9.3%100% | 24−14.1%100% | 27*−68.0%100% | 25—100% | 24—100% | 28—100% | 84*—100% | |
| Cost of revenue | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0*−100%0.0% | 0.6+340%2.1% | 0.2+111%0.9% | 0.1+28.0%0.6% | 0.1*−54.6%0.4% | 0.1—0.6% | 0.1—0.5% | 0.1—0.4% | 0.3*—0.3% | |
| Research and development | 46−56.7%34.1% | 12−50.6%37.0% | 15−44.7%42.8% | 12−45.1%35.0% | 7.5*−77.8%22.0% | 24−42.5%78.0% | 27−27.4%104% | 22−51.0%89.4% | 34*−49.4%126% | 41—163% | 37—156% | 44—157% | 67*—79.6% | |
| General and administrative | 36−42.8%26.9% | 8.4−22.3%26.8% | 8.5−45.4%24.5% | 6.9−56.4%20.3% | 12*−41.3%35.9% | 11−37.1%35.9% | 16−7.7%60.4% | 16−6.7%65.3% | 21*−1.2%78.0% | 17—68.8% | 17—71.5% | 17—60.2% | 21*—25.3% | |
| Total costs and expenses | — | 20−42.3%63.8% | 23−45.2%67.3% | 19−50.0%55.4% | — | 35—115% | 42—165% | 37—155% | — | — | — | — | — | |
| Operating income | 52—38.9% | 11—36.2% | 11—32.7% | 15—44.6% | 14*—42.1% | −4.5—−15.0% | −17—−65.0% | −13—−55.3% | −26*—−96.5% | −32—−125% | −30—−128% | −33—−117% | −4.2*—−5.0% | |
| Interest and finance income | 0.6−21.1%0.4% | 0.4+462%1.3% | 0.1+124%0.4% | 0.0−88.8%0.1% | 0.0*−93.0%0.1% | 0.1−92.7%0.2% | 0.1−90.0%0.2% | 0.2−76.7%0.8% | 0.4*—1.6% | 1.0—4.1% | 0.5—2.3% | 0.8—2.9% | — | |
| Interest expense and finance costs | 61+0.6%45.6% | 15+12.8%47.4% | 15+15.1%44.5% | 15+13.1%43.5% | 16*−24.0%46.9% | 13−64.0%43.8% | 13−58.7%51.9% | 13−57.1%53.9% | 21*—78.7% | 37—146% | 32—137% | 30—108% | — | |
| Share of profit of associates | −23—−17.4% | 1.9—5.9% | 2.5—7.3% | −1.4—−4.0% | −26*—−77.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Other non-operating income (expense) | 22—16.4% | 4.0—12.6% | 0.9—2.5% | −0.2—−0.6% | 17*—50.7% | −19−101668%−63.8% | −0.0−100%−0.0% | −0.3—−1.1% | −0.2*—−0.8% | 0.0—0.1% | 7.1—30.4% | −1.1—−3.9% | −0.2*—−0.2% | |
| Net income including minority interests | 31—23.0% | 2.7−95.7%8.7% | −0.6—−1.6% | 39—116% | −11*—−31.0% | 64—211% | −30—−117% | −26—−110% | −47*—−174% | −67—−268% | −55—−233% | −63—−227% | −49r−49*—−58.0% | |
| Minority interests' share of net income | −0.1—−0.1% | −0.0—−0.0% | −0.0—−0.0% | −0.0—−0.1% | −0.0*—−0.1% | −0.0—−0.0% | −2.1—−8.0% | −1.1—−4.6% | −0.9*—−3.5% | −0.8—−3.3% | −1.7—−7.3% | −1.6—−5.6% | −2.3*—−2.7% | |
| Earnings per share, basic | — | 0.02−99.0%— | -0.01—— | 1.03—— | — | 2.00—— | -1.00—— | -1.03—— | — | -3.08—— | -2.52—— | -3.04—— | — | |
| Earnings per share, diluted | — | 0.02−99.0%— | -0.01—— | 1.02—— | — | 1.94—— | -1.00—— | -1.03—— | — | -3.08—— | -2.52—— | -3.04—— | — | |
| Shares, weighted average (basic) | 63+96.5%— | 63+96.5%— | 41+47.0%— | 38+55.1%— | — | 32+48.0%— | 28+33.5%— | 24+20.1%— | — | 22—— | 21—— | 20—— | — | |
| Shares, weighted average (diluted) | 83+153%— | 83+153%— | 41+47.0%— | 38+56.5%— | — | 33+52.5%— | 28+33.5%— | 24+20.1%— | — | 22—— | 21—— | 20—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 67—27.3% | 67+1836%27.3% | 19+96.5%10.9% | 35+89.3%18.8% | 3.0−92.6%1.3% | 3.5−92.3%1.5% | 9.5−89.8%5.1% | 18−65.0%9.2% | 40−46.9%17.9% | 45—18.8% | 94—32.1% | 53—20.6% | 76—24.2% | |
| Short-term investments | 20—8.1% | 20—8.1% | — | — | 0—0.0% | — | — | — | — | — | — | — | — | |
| Receivables | 17—7.0% | 17+3074%7.0% | 15+1977%8.5% | 6.6+1754%3.5% | 1.8+350%0.8% | 0.5+160%0.2% | 0.7−1.4%0.4% | 0.4−25.6%0.2% | 0.4−98.4%0.2% | 0.2—0.1% | 0.7—0.2% | 0.5—0.2% | 26—8.2% | |
| Other current assets | 2.1—0.8% | 2.1+72.1%0.8% | 2.0+14.7%1.2% | 2.0−15.9%1.1% | 1.1−54.9%0.5% | 1.2−57.5%0.5% | 1.8−47.5%1.0% | 2.4−22.4%1.2% | 2.4+1.8%1.1% | 2.8—1.2% | 3.4—1.1% | 3.1—1.2% | 2.4—0.8% | |
| Current assets | 148—60.4% | 148+10.7%60.4% | 79+491%45.6% | 95+312%51.1% | 133+193%58.8% | 134+167%57.3% | 13−86.7%7.2% | 23−61.7%11.6% | 46−59.5%20.1% | 50—21.0% | 100—34.2% | 60—23.5% | 112—35.8% | |
| Property, plant and equipment | 14—5.7% | 14−13.1%5.7% | 14−87.3%8.3% | 15−87.2%8.0% | 15−87.1%6.8% | 16−87.2%6.8% | 113−11.6%60.9% | 117−10.2%58.5% | 120−10.0%53.1% | 124—52.2% | 128—43.6% | 130—50.8% | 133—42.5% | |
| Right-of-use (leased) assets | 6.9—2.8% | 6.9−13.4%2.8% | 7.2−72.7%4.2% | 7.5−72.4%4.0% | 7.7−71.6%3.4% | 8.0−71.9%3.4% | 26−8.8%14.3% | 27−7.8%13.5% | 27−7.8%12.1% | 29—12.0% | 29—9.9% | 29—11.4% | 30—9.4% | |
| Goodwill | 24—9.8% | 240.0%9.8% | 240.0%14.0% | 240.0%12.9% | 240.0%10.6% | 24−2.4%10.3% | 24−2.7%13.0% | 24−2.5%12.0% | 24−2.6%10.6% | 25—10.4% | 25—8.5% | 25—9.6% | 25—7.9% | |
| Other intangible assets | 2.8—1.1% | 2.8−10.2%1.1% | 2.9−10.2%1.7% | 3.0−10.1%1.6% | 3.0−10.0%1.3% | 3.1−21.1%1.3% | 3.2−22.5%1.7% | 3.3−22.2%1.6% | 3.4−23.5%1.5% | 4.0—1.7% | 4.1—1.4% | 4.2—1.6% | 4.4—1.4% | |
| Investments in associates | 27—11.1% | 27−10.4%11.1% | 25—14.7% | 23—12.3% | 24—10.7% | 30—13.0% | — | — | 0—0.0% | — | — | — | — | |
| Total assets | 246—100% | 246+5.0%100% | 173−6.8%100% | 186−6.9%100% | 227+0.2%100% | 234−1.9%100% | 185−36.7%100% | 200−22.0%100% | 226−27.9%100% | 238—100% | 292—100% | 257—100% | 314—100% | |
| Accounts payable | 47—19.0% | 47−45.2%19.0% | 59−20.7%34.2% | 71+10.7%38.1% | 83+35.0%36.6% | 85+85.8%36.5% | 74+46.3%40.2% | 64+26.7%32.1% | 61+0.0%27.2% | 46—19.2% | 51—17.4% | 51—19.8% | 61—19.6% | |
| Debt due within a year | — | — | 30+180%17.4% | 30+4030%16.2% | 45+1555%19.7% | 11−20.8%4.5% | 11−20.1%5.8% | 0.7−94.6%0.4% | 2.7+1748%1.2% | 13—5.6% | 13—4.6% | 14—5.3% | 0.1—0.0% | |
| Current liabilities | 204—83.0% | 204−29.1%83.0% | 232−1.2%134% | 249+19.7%134% | 323+46.1%143% | 287+6.1%123% | 235−13.3%127% | 208−18.6%104% | 221−13.5%97.8% | 271—113% | 271—92.6% | 256—99.8% | 256—81.5% | |
| Long-term debt | 24—9.9% | 24+3.5%9.9% | — | — | 0−100%0.0% | 24—10.1% | 23—12.5% | 33—16.4% | 30+139%13.5% | 0—0.0% | 0—0.0% | 0—0.0% | 13—4.1% | |
| Lease liabilities (non-current) | 8.7—3.6% | 8.7−15.9%3.6% | 9.5−82.1%5.5% | 9.8−81.8%5.3% | 10−81.5%4.5% | 10−81.2%4.4% | 53−4.3%28.8% | 54−12.6%27.0% | 55−12.7%24.1% | 55—23.1% | 56—19.1% | 62—24.1% | 63—19.9% | |
| Retained earnings | −2,141—−872% | −2,141—−872% | −2,144—−1242% | −2,144—−1150% | −2,183—−962% | −2,172—−929% | −2,236—−1207% | −2,208—−1103% | −2,183—−965% | −2,137—−896% | −2,071—−708% | −2,018—−786% | −1,956—−623% | |
| Shareholders' equity | −105—−42.9% | −105—−42.9% | −199—−115% | −221—−119% | −271—−120% | −274—−117% | −355—−191% | −342—−171% | −326—−144% | −292—−123% | −241—−82.5% | −201—−78.5% | −160—−51.1% | |
| Minority interests | −6.8—−2.8% | −6.8—−2.8% | −6.8−137%−3.9% | −6.8−135%−3.6% | −6.8−134%−3.0% | −6.7−133%−2.9% | 18−10.6%9.9% | 19+75.1%9.7% | 20+67.0%8.8% | 21—8.6% | 20—7.0% | 11—4.3% | 12—3.8% | |
| Total equity | −112—−45.7% | −112—−45.7% | −206—−119% | −228—−122% | −278—−123% | −281—−120% | −336—−182% | −322—−161% | −306—−135% | −272—−114% | −221—−75.5% | −190—−74.2% | −148—−47.3% | |
| Total liabilities and equity | 246—100% | 246+5.0%100% | 173−6.8%100% | 186−6.9%100% | 227+0.2%100% | 234−1.9%100% | 185−36.7%100% | 200−22.0%100% | 226−27.9%100% | 238—100% | 292—100% | 257—100% | 314—100% | |
| Shares outstanding | 45—— | 45+37.8%— | 43+42.0%— | 39+45.0%— | 35+49.4%— | 33+51.3%— | 30+42.0%— | 27+26.5%— | 24+19.9%— | 22—— | 21—— | 21—— | 20—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 2.2−82.5%1.6% | 0.5*−83.1%1.6% | 0.5*−83.7%1.5% | 0.6−81.8%1.7% | 0.6*−81.7%1.7% | 3.0*−9.4%10.0% | 3.2*−5.8%12.3% | 3.2−5.1%13.3% | 3.3*−37.3%12.1% | 3.3*—13.3% | 3.4*—14.3% | 3.4—12.0% | 5.2*—6.2% | |
| Share-based compensation | 11−25.5%8.0% | 2.9+3.9%9.3% | 3.3−5.3%9.4% | 1.1−68.5%3.3% | 3.5*−26.0%10.1% | 2.8−69.7%9.3% | 3.4−63.0%13.4% | 3.5−16.1%14.5% | 4.7*−14.4%17.4% | 9.3—37.0% | 9.3—39.5% | 4.2—14.8% | 5.5*—6.5% | |
| Cash from operating activities | −104—−77.5% | −20*—−63.8% | −31*—−90.4% | −36—−107% | −17*—−48.6% | −15*—−48.7% | −20*—−78.7% | −26—−106% | −29*—−107% | −53*—−212% | −38*—−162% | −38—−136% | −40*—−48.2% | |
| Capital expenditure | 0—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | −0.0*—−0.0% | −0.0—−0.0% | −0.1*—−0.3% | −0.0*—−0.0% | −0.5*—−2.0% | −0.0—−0.1% | −0.2*—−0.3% | |
| Cash from investing activities | 50+12654%37.4% | −20*−26254%−63.1% | 0.3*−5.0%0.8% | 69+120868%204% | 0.8*—2.3% | 0.1*+35.7%0.3% | 0.3*—1.1% | 0.1−75.1%0.2% | −0.0*−101%−0.1% | 0.1*—0.2% | −0.2*—−1.0% | 0.2—0.8% | 2.8*—3.4% | |
| Debt repaid | −8.4—−6.3% | 0*—0.0% | 0*—0.0% | −8.4—−24.9% | 0*—0.0% | 0*—0.0% | 0*—0.0% | −2.5—−10.4% | — | 0*—0.0% | — | — | — | |
| Cash from financing activities | 117+156%87.1% | 88*+1210%278% | 15*+34.2%42.5% | −1.0−128%−2.9% | 15*−36.9%44.9% | 6.7*+46.7%22.1% | 11*−86.2%42.6% | 3.6−75.8%14.9% | 24*+233%90.8% | 4.6*—18.1% | 79*—336% | 15—53.0% | 7.3*—8.7% | |
| Change in cash | 63—46.9% | 48*—151% | −16*—−47.1% | 32—94.8% | −0.5*—−1.3% | −8.0*—−26.5% | −9.0*−122%−34.9% | −22—−91.2% | −4.3*—−16.2% | −49*—−195% | 41*—174% | −23—−83.0% | −30*—−36.0% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Agenus Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Non-Cash Revenue Related to the Sale of Future Royalties$109 M95%+7.5%
- Non-cash royalties$109 M95%+7.5%
- Pre-Commercial Product Revenue$4 M3.7%—
- Other services$1 M0.9%-48%
- Service Revenue$1 M0.9%-48%
- Research and Development$0 M0.3%-31%
- Clinical product revenue$0 M0.3%-31%
Countries and regions
- 🇺🇸 USA$113 M99%+12%
- Rest of World(total)$1 M0.9%-48%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Agenus Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Armen | $1.4 M | $3.6 M | $617 K | $7 |
| 2024Dr. Armen | $4.1 M | $2.9 M | $927 K | $3 |
| 2023Dr. Armen | $5.9 M | −$1.5 M | $1.1 M | $20 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Agenus Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 8 · Agreement ended 1 · New debt 4 · Unregistered share sale 5 · Shareholder rights changed 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completedUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Material agreementShareholder rights changed | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Agreement ended | 8-K | |
| Restructuring | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K/A |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2019 | $30 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| Oct 2018 | $40 M | Private placement after listing | $10 to $50 million | 2 | equity | SEC |
| Feb 2017 | $60 M | Private placement after listing | $50 to $250 million | 1 | equity | SEC |
| Dec 2015 | $7 M | Private placement after listing | $2 to $10 million | 17 | equity | SEC |
| Sep 2015 | $2 M | Private placement after listing | $2 to $10 million | 2 | equity | SEC |
| Feb 2015 | $21 M | Private placement after listing | $10 to $50 million | 8 | debt, options | SEC |
| Feb 2015 | $35 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| Apr 2013 | $5 M | Private placement after listing | $2 to $10 million | 3 | debt, options | SEC |
| Aug 2009 | $10 M | Private placement after listing | $10 to $50 million | 4 | equity, options | SEC |
| Aug 2009 | $10 M | Private placement after listing | $10 to $50 million | 1 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Agenus Inc.#
$30 K spent on lobbying the US Congress and federal agencies in 2024, most often on medical/disease research/clinical labs and health issues.
- Medical/Disease Research/Clinical Labs1 report
- Health Issues1 report
Lobbying firms hired in 2024
TIDES GROUP, LLC $30 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2024 | $30 K | — | 1 |
| 2023 | $105 K | — | 3 |
| 2019 | $0 | — | 2 |
| 2018 | $20 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Agenus Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Agenus Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $250 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Director, Statistical ProgrammingBiostatisticians | 1 | $250 K |
Where: Piscataway, NJ 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $250 K | 1 |
| FY2025 | 4 | 4 | $140 K | 4 |
| FY2024 | 3 | 3 | $191 K | 3 |
| FY2023 | 4 | 4 | $96 K | 4 |
| FY2022 | 7 | 7 | $88 K | 7 |
| FY2021 | 8 | 8 | $100 K | 8 |
| FY2020 | 5 | 5 | $102 K | 5 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Agenus Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2009 | · | 19 | · | · | · | · | · | · | · | · | · | · | 19 |
| 2006 | · | · | · | · | 42 | · | · | · | · | · | · | · | 42 |
| 2005 | · | · | · | · | · | · | · | · | · | · | · | 70 | 70 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 25% of workforce | Restructuring planSEC 8-K | “(excluding its independently operating subsidiaries) is reducing its workforce by approximately 25%, which the company expects to result in savings of approximately $2.8 million by…” | Filing | |
| 19 people (20% of workforce) | Restructuring planSEC 8-K | “(the “Company”) initiated a plan of restructuring that resulted in a reduction of its workforce by approximately 20%, or 19 positions.” | Filing | |
| 42 people | Restructuring planSEC 8-K | “During the quarter ending June 30, 2006, the Company will eliminate 42 positions and has estimated its costs related to this reduction to be approximately $535,000.” | Filing | |
| 70 people | Restructuring planSEC 8-K | “As part of these strategies, the Company has terminated approximately 70 employees and has estimated its costs related to these terminations and other related activities to be appr…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Agenus Inc. compares in Biotechnology
- Market cap$290 M · higher than 50% of 726
- Revenue$114 M · higher than 70% of 647
- Net margin23.0% · higher than 88% of 408
- Revenue growth10.4% · higher than 54% of 438
- P/E ratio9.4× · lower than 75% of 100
- Price / sales2.2× · lower than 84% of 339
- FCF yield-26.7% · higher than 37% of 449
- 🇺🇸 Eikon Therapeutics, Inc.$290 M
- 🇺🇸 SAB Biotherapeutics, Inc.$291 M
- 🇺🇸 Alector, Inc.$293 M
- 🇺🇸 Vogenx, Inc.$296 M
- 🇺🇸 Fulcrum Therapeutics, Inc.$283 M
- 🇮🇪 Amarin Corporation$297 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Agenus Inc.🇺🇸 | $290 M | 9.4× | 23.0% | +10.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 22, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikidata, Wikipedia, Wikimedia Commons, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Agenus Inc.? Verify and update this profile — free
Show Agenus Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.